Bystolic (nebivolol) / Menarini, AbbVie - LARVOL DELTA

Urinary Bladder Paraganglioma With POT1 and RECQL4 Mutations Almost Missed by Ga-68 DOTATATE PET/CT (ENDO 2025) - "Spironolactone therapy improved blood pressure (BP) control; however, BP spikes continued along with headaches occasionally associated with voiding/bowel movements. Medications were amlodipine 10 mg/day, eplerenone 50 mg BID, nebivolol 5 mg/day, doxazosin 2 mg nightly... Bladder paragangliomas pose a diagnostic challenge. As illustrated in this case, Ga68-DOTATATE PET/CT initially missed this lesion due to the urinary excretion of the tracer highlighting the need for other imaging modalities when considering bladder PGLs. Further studies examining whether POT1 or REQL4 mutations might be pathogenic for (urinary) PGLs are warranted."

Bladder Cancer • Cardiovascular • Colonic Polyps • Endocrine Cancer • Endocrine Disorders • Follicular Lymphoma • Gastroenterology • Hematological Malignancies • Hodgkin Lymphoma • Hypertension • Lymphoma • Neuroendocrine Tumor • Oncology • Pain • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • POT1 • RECQL4 • SDHB • SYP • TP63

Calcium triggers calmodulin degradation to induce EGF receptor instability and overcome non-small cell lung cancer resistance to tyrosine kinase inhibitors. (PubMed, J Biol Chem) - "Notably, a combination of Ca2+ activator curcumin, FBXL2 activator nebivolol, and osimertinib significantly inhibits EGFRT790M/C797S-driven TKI-resistant NSCLC growth. Together, this study highlights the importance of the negative feedback loop between Ca2+ and CaM and the critical regulatory role of Ca2+/CaM in the FBXL2-mediated EGFR degradation, providing a viable therapeutic strategy for TKI-resistant NSCLC."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • FBXL2

Impact of beta-blocker nebivolol versus carvedilol prescription at discharge on long-term clinical outcomes in STEMI patients with reduced LVEF treated with drug-eluting stents (ESC-WCC 2025) - No abstract available

Clinical • Clinical data • Acute Coronary Syndrome • Cardiovascular

Impact of Nebivolol versus Carvedilol on long-term outcomes on long-term clinical outcomes in ST-elevation myocardial infarction patients with mid-range left ventricular ejection fraction (40% to 49%) (ESC-WCC 2025) - No abstract available

Clinical • Clinical data • Cardiovascular • Myocardial Infarction

Impact of nebivolol versus bisoprolol on long-term clinical outcomes in STEMI patients treated with drug-eluting stents (ESC-WCC 2025) - No abstract available

Clinical • Clinical data • Cardiovascular

Impact of nebivolol versus carvedilol on long-term clinical outcomes in STEMI patients treated with drug-eluting stents (ESC-WCC 2025) - No abstract available

Clinical • Clinical data • Cardiovascular

Impact of beta-blocker Nebivolol versus Carvedilol prescription at discharge on long-term clinical outcomes in STEMI patients with preserved LVEF treated with drug-eluting stents (ESC-WCC 2025) - No abstract available

Clinical • Clinical data • Acute Coronary Syndrome • Cardiovascular

Advanced eco-friendly spectrophotometric analysis for Nebivolol, Valsartan, and related impurity with comprehensive environmental impact assessment. (PubMed, Sci Rep) - "The proposed methods were validated as per ICH guidelines and verified to be accurate. Statistical analysis was performed to ensure the validity of methods concerning published methods."

Journal

Predictors of graft patency following coronary artery bypass graft surgery: the role of nebivolol therapy. (PubMed, Geroscience) - "Nebivolol has been found to reduce the frequency of graft occlusion following CABG, especially in case of SVG grafts. The vasodilatory properties of nebivolol may, at least in part, be responsible for the favorable effects of the drug to prevent graft occlusion."

Journal • Cardiovascular • Peripheral Arterial Disease

ARTEMISIA: Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients (clinicaltrials.gov) - P4 | N=266 | Completed | Sponsor: Menarini International Operations Luxembourg SA | Recruiting ➔ Completed

Trial completion • Cardiovascular • Hypertension

Prospective Observational Study On The Impact Of Nebilet In Blood Pressure Control In Hypertensive Patients (HYIMPACT) (clinicaltrials.gov) - P=N/A | N=4537 | Recruiting | Sponsor: A.Menarini Asia-Pacific Holdings Pte Ltd

New trial • Cardiovascular • Hypertension

In vitro-in vivo scaling of cytochrome P450-mediated metabolic clearance using a relative activity factor approach. (PubMed, Drug Metab Dispos) - "We selected multiple probe substrates for CYP1A2 (caffeine, tizanidine, phenacetin), CYP2C9 ((S)-acenocoumarol, glimepiride, lornoxicam, tolbutamide, (S)-warfarin), CYP2C19 ((S)-lansoprazole, omeprazole, pantoprazole), CYP2D6 (desipramine, metoprolol, nebivolol, tolterodine), and CYP3A4 (alprazolam, felodipine, midazolam, nisoldipine, sildenafil, triazolam) to calculate the representative RAF value for each P450 isoform based on the in vivo-to-in vitro clearance ratio of the multiple probe substrates...The fm values of the responsible P450 isoform(s) could be well predicted for mexiletine, tamsulosin, risperidone, celecoxib, and glibenclamide...By applying relative activity factor values obtained from multiple probe substrates, this study was able to quantitatively predict the in vivo clearances mediated by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. This simple, practical method will help optimize metabolic clearances via the major cytochrome P450..."

Journal • Preclinical • CYP1A2 • CYP2C19 • CYP2C9 • CYP3A4

DANBLOCK: Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction (clinicaltrials.gov) - P4 | N=2760 | Active, not recruiting | Sponsor: Bispebjerg Hospital | Trial completion date: Apr 2025 ➔ Dec 2035

Trial completion date • Cardiovascular • Congestive Heart Failure • Myocardial Infarction

A CASE REPORT OF SWALLOWING INDUCED ATRIAL TACHYCARDIA - Travis Hanson (ACC 2025) - "This 46-year-old male with palpitations, intermittent chest pain, and lightheadedness while swallowing was diagnosed with SIAT. The patient's symptoms have been well managed with metoprolol and diltiazem."

Case report • Clinical • Cardiovascular • Pain

EFFICACY OF NEBIVOLOL/VALSARTAN COMBINED PILL FOR ANTI-HYPERTENSIVE THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS - Talal Warsi (ACC 2025) - "The N/V combination pill significantly reduces systolic blood pressure SBP in comparison to valsartan, valsartan/amlodipine, or nebivolol, and DBP relative to nebivolol. However, it is important to consider limitations such as small sample size, lack of gender-specific data, and unreported adverse effects. Further comprehensive studies are needed to support the safety and effectiveness of N/V combination pills in different demographic subgroups."

Retrospective data • Review • Cardiovascular • Hypertension

Nebivolol rescued the liver and kidney from the coadministration of rivaroxaban and cisplatin by targeting inflammation, oxidative stress, and apoptosis in rats. (PubMed, Int Immunopharmacol) - "Moreover, nebivolol lowered the levels of caspase-3 in the liver and NF-κB in the kidneys. In conclusion, our study indicates that nebivolol protects the liver and kidneys from the detrimental effects of cisplatin and rivaroxaban."

Journal • Preclinical • Hepatology • Inflammation • Liver Failure • Oncology • Solid Tumor • CASP3 • IL6 • NFKB1 • TNFA

Mechanisms of nebivolol-mediated effects on bFGF-induced vascular smooth muscle cell proliferation and migration. (PubMed, Curr Res Pharmacol Drug Discov) - "The enhancement on bFGF-induced cell proliferation at lower concentrations appears to be mainly mediated by activation of β3-ARs but the inhibitory effects on bFGF-mediated cell proliferation as well as migration may occur through different mechanisms. AKT signaling is only involved in high concentrations of nebivolol-mediated effects."

Journal

An Energy Metabolism Nanoblocker for Cutting Tumor Cell Respiration and Inhibiting Mitochondrial Hijacking from Cytotoxic T Lymphocyte. (PubMed, Adv Healthc Mater) - "In this study, a CD44 receptor-targeted hyaluronic acid energy metabolism nanoblocker is developed to achieve bidirectional blockade of basal respiration in tumor cells with the loaded mitochondrial oxidative phosphorylation (OXPHOS) inhibitor nebivolol hydrochloride, and the glycolysis inhibitor 3-bromopyruvate...This emerging strategy, which involves depleting tumor cell energy through inhibition of basal respiration (OXPHOS/glycolysis) and extra respiration, while synergistically enhancing effector immune cells to maintain systemic anti-tumor immune effects, demonstrates high efficacy and safety in both in vitro and in vivo experiments. It provides a conceptual paradigm shift in nanomedicine-mediated energy metabolism-based tumor therapy."

Journal • Oncology

Posttreatment pulse rate reduction and not baseline pulse rate as an indicator of blood pressure response to nebivolol: a subanalysis from the real-world BENEFIT-KOREA study. (PubMed, Clin Hypertens) - P=N/A | "These findings suggest the presence of other mechanisms in addition to sympathetic inhibition which potentially weaken the relationship between baseline PR and BP reduction. ClinicalTrials.gov Identifier: NCT03847350."

Journal • Real-world evidence • Cardiovascular • Hypertension

Membranous Nephropathy after mRNA 1273 (NKF-SCM 2025) - "mRNA 1273.214 was given one month prior.Results Creatinine is 1.01 to 1.40 mg/dl...Light microscopic, immunofluorescence staining for IgG, and electron microscopy specimens are shown below:Conclusion The patient was maintained on telmisartan, nebivolol, dapagliflozin, metformin, glipizide, evolocumab, and atorvastatin...Boosting with five doses of the vaccine and exposure to the Covid-19 virus may all have exacerbated this autoimmune response. The diminution of proteinuria from 2888 milligrams to 2112 milligrams 21 days later to 203 mg nineteen months after the final vaccine administration suggest that the antigen antibody complexes deposited in the glomerular basement membrane cleared and that the biopsy documented membranous nephropathy at the time of the acute proteinuria has resolved."

Glomerulonephritis • Hematological Disorders • Hepatitis B • Hepatitis C • Hepatology • Immunology • Infectious Disease • Novel Coronavirus Disease • Oncology • Renal Disease • C1QB • NELL1

Nebivolol attenuates acute systemic inflammation induced testicular dysfunction by decreasing transendothelial migration via VCAM-1/MMP-9 signaling. (PubMed, J Mol Histol) - "NB administration successfully restored all these changes significantly. Thus, NB can be a protective drug candidate for testicular dysfunction secondary to systemic inflammation with its potent antioxidant and anti-inflammatory mechanisms."

Journal • Inflammation • Oncology • CASP3 • MMP9 • TNFA • VCAM1

Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging (clinicaltrials.gov) - P2 | N=5 | Terminated | Sponsor: Stanford University | N=360 ➔ 5 | Trial completion date: Jun 2025 ➔ Oct 2024 | Suspended ➔ Terminated; Low recruitment, insufficient funding

Enrollment change • Trial completion date • Trial termination • Cardiovascular

Target the Heart: a new axis of Alzheimer's disease prevention. (PubMed, bioRxiv) - "This indicates that co-administering a low dose of cyclosporine A with select cardiac drugs could be a potentially effective treatment strategy for Alzheimer's disease and cardiovascular dysfunction, while mitigating side effects associated with higher doses of cyclosporine A. Given that heart disease precedes Alzheimer's disease in many patients, physicians may be able to create a treatment regimen that simultaneously addresses both conditions. Our results suggest that cyclosporine A combined with simvastatin, irbesartan, cilostazol, doxazosin, or nebivolol are the most promising candidates for future exploration."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Heart Failure

Comparison of nebivolol, carvedilol, and bisoprolol for adverse clinical outcomes among patients with heart failure-a real-world nationwide investigation. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Nebivolol cohorts had a lower risk of CV deaths and all-cause deaths than the non-BB cohort (adjusted HR = 0.77, 95% CI = 0.69-0.85; adjusted HR = 0.78, 95% CI = 0.73-0.83). The authors concluded that the use of nebivolol was associated with better outcomes in patients with HF."

Adverse events • Clinical data • Journal • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure

Role of β-Adrenergic Receptors in Stress-Induced Cardiac Injury. (PubMed, Bull Exp Biol Med) - "β1-AR antagonists nebivolol and atenolol almost completely prevented SICI. Stimulation of β2-AR enhances cardiac tolerance to stress. β3-AR are not involved in the pathogenesis of SICI."

Journal